Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4E | P06730 | 14/20 | 0.49 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6879060 | 0.89 | KDM4E (0.53) | EIF4EKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5045711 | 0.89 | KDM4E (0.55) | EIF4EPPARGKDM4ENPC1RAB9A | |
| SCHEMBL5039946 | 0.88 | EIF4E (0.42) | EIF4EPPARGNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6471994 | 0.87 | KDM4E (0.51) | EIF4EKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6884109 | 0.86 | EIF4E (0.57) | EIF4EKDM4ENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5049089 | 0.86 | HPGD (0.44) | EIF4ENPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5048709 | 0.86 | HPGD (0.45) | EIF4EPPARGKDM4ENPC1RAB9A | |
| SCHEMBL6881059 | 0.85 | EIF4E (0.50) | EIF4EPPARGKDM4ENPC1RAB9A | |
| SCHEMBL5044005 | 0.85 | LMNA (0.46) | EIF4EPPARGKDM4ENPC1RAB9A | |
| SCHEMBL6883231 | 0.84 | KDM4E (0.50) | EIF4EKDM4ENPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583762-B1 | PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-07-09 | — | — | EP | disclosed |
| US-7135488-B2 | Pyrrolyl-thiazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1583762-A1 | PYRROLYL-THIAZOLES AND THEIR USE AS CB 1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-10-12 | — | — | EP | disclosed |
| US-20040147572-A1 | Novel pyrrolyl-thiazole derivatives | HOFFMAN-LA ROCHE INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004060888-A1 | NOVEL CB 1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147572-A1 | Novel pyrrolyl-thiazole derivatives | CNR1, CNR2, NPY1R | EIF4E 2174/4885PPARG 103/4885KDM4E 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.